<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rentrad</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник рентгенологии и радиологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal of radiology and nuclear medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0042-4676</issn><issn pub-type="epub">2619-0478</issn><publisher><publisher-name>Limited Liability Company "LUCHEVAYA DIAGNOSTIKA", Russian Association of Radiologists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20862/0042-4676-2019-100-5-263-269</article-id><article-id custom-type="elpub" pub-id-type="custom">rentrad-502</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Радиобиологическая оценка дозиметрических планов для стереотаксической радиотерапии рака предстательной железы в зависимости от режима фракционирования</article-title><trans-title-group xml:lang="en"><trans-title>Radiobiological Evaluation of Dosimetric Plans for Stereotactic Radiotherapy for Prostate Cancer According to Fractionation Regimen</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сухих</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhikh</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сухих Евгения Сергеевна, к. ф.-м. н., доцент; начальник отдела медицинской физики радио-терапевтического отделения</p><p>пр-т Ленина, 30, Томск, 634050; пр-т Ленина, 115, Томск, 634050</p></bio><bio xml:lang="en"><p>Evgeniya S. Sukhikh, Cand. Phys.-Math. Sc., Associate Professor; Head of Medical Physics Division, Radiotherapy Department</p><p>prospekt Lenina, 30, Tomsk, 634050, Russian Federation; prospekt Lenina, 115, Tomsk, 634050, Russian Federation</p></bio><email xlink:type="simple">e.s.sukhikh@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шейно</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sheyno</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шейно Игорь Николаевич, к. ф.-м. н., заведующий лабораторией методов и технологий лучевой терапии</p><p>ул. Живописная, 46, Москва, 123182</p></bio><bio xml:lang="en"><p>Igor' N. Sheyno, Cand. Phys.-Math. Sc., Head of Laboratory for Methods and Technologies Radiation Therapy</p><p>ul. Zhivopisnaya, 46, Moscow, 123182, Russian Federation</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сухих</surname><given-names>Л. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Sukhikh</surname><given-names>L. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сухих Леонид Григорьевич, д. ф.-м. н., директор исследовательской школы физики высокоэнергетических процессов</p><p>пр-т Ленина, 30, Томск, 634050</p></bio><bio xml:lang="en"><p>Leonid G. Sukhikh, Dr. Phys.-Math. Sc., Director, Research School of Physics of High-Energy Processes</p><p>prospekt Lenina, 30, Tomsk, 634050, Russian Federation</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Талецкий</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Taletskiy</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Талецкий Александр Владимирович, врач-радиотерапевт радиотерапевтического отделения</p><p>пр-т Ленина, 115, Томск, 634050</p></bio><bio xml:lang="en"><p>Aleksandr V. Taletskiy, Radiotherapist, Radiotherapy Department</p><p>prospekt Lenina, 115, Tomsk, 634050, Russian Federation</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вертинский</surname><given-names>А. В. </given-names></name><name name-style="western" xml:lang="en"><surname>Vertinskiy</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вертинский Андрей Владимирович, медицинский физик отдела медицинской физики радиотерапевтического отделения</p><p>пр-т Ленина, 115, Томск, 634050</p></bio><bio xml:lang="en"><p>Аndrey V. Vertinskiy, Medical Physicist, Medical Physics Division, Radiotherapy Department</p><p>prospekt Lenina, 115, Tomsk, 634050, Russian Federation</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ижевский</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Izhevskiy</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ижевский Павел Владимирович, к. м. н., доцент, вед. науч. сотр. лаборатории методов и технологий лучевой терапии</p><p>ул. Живописная, 46, Москва, 123182</p></bio><bio xml:lang="en"><p>Pavel V. Izhevskiy, Cand. Med. Sc., Associate Professor, Leading Researcher, Laboratory for Methods and Technologies of Radiation Therapy</p><p>ul. Zhivopisnaya, 46, Moscow, 123182, Russian Federation</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Национальный исследовательский Томский политехнический университет»; ОГАУЗ «Томский областной онкологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Tomsk Polytechnic University; Tomsk Regional Oncology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Государственный научный центр – Федеральный медицинский биофизический центр имени А.И. Бурназяна» Федерального медико-биологического агентства России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Research Center – Burnasyan Federal Medical Biophysical Center, Federal Medical Biological Agency of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГАОУ ВО «Национальный исследовательский Томский политехнический университет»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Tomsk Polytechnic University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ОГАУЗ «Томский областной онкологический диспансер»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tomsk Regional Oncology Dispensary</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>04</day><month>11</month><year>2019</year></pub-date><volume>100</volume><issue>5</issue><fpage>263</fpage><lpage>269</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сухих Е.С., Шейно И.Н., Сухих Л.Г., Талецкий А.В., Вертинский А.В., Ижевский П.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Сухих Е.С., Шейно И.Н., Сухих Л.Г., Талецкий А.В., Вертинский А.В., Ижевский П.В.</copyright-holder><copyright-holder xml:lang="en">Sukhikh E.S., Sheyno I.N., Sukhikh L.G., Taletskiy A.V., Vertinskiy A.V., Izhevskiy P.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.russianradiology.ru/jour/article/view/502">https://www.russianradiology.ru/jour/article/view/502</self-uri><abstract><sec><title>Цель</title><p>Цель. Определение наиболее эффективного режима облучения пациента (общая доза и доза за фракцию) для гипофракционированного лечения карцином предстательной железы на основе радиобиологических критериев вероятности локального контроля опухоли (TCP) и вероятности осложнений в нормальных тканях (NTCP).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. На примере томографической информации 5 пациентов с аденокарциномой предстательной железы низкого риска созданы дозиметрические планы облучения с использованием методики объемной модуляции интенсивности излучения. Рассмотрен диапазон общих доз от 33,5 до 38 Гр, подводимых за 4 и 5 фракций. На основе концепции эквивалентной равномерной дозы А. Niemierko на базе рассчитанных дифференциальных гистограмм «доза–объем» смоделированы величины TCP с учетом неопределенностей основных радиобиологических параметров и рассчитаны показатели NTCP для передней стенки прямой кишки как наиболее облучаемого органа риска. Отбор эффективного дозиметрического плана проводился по критерию вероятности контроля опухоли без лучевых осложнений (UTCP), то есть TCP×(1–NTCP).</p></sec><sec><title>Результаты</title><p>Результаты. Результаты моделирования критерия UTCP показывают, что при увеличении суммарной дозы растет величина TCP, но возрастает и величина NTCP, поэтому оптимальными планами облучения являются облучение суммарной дозой 34 Гр за 4 фракции или дозой 36–37 Гр за 5 фракций. Разница между режимами фракционирования заключается в том, что при 4 фракциях значение критерия UTCP достигается за счет большего значения TCP, а при 5 фракциях – за счет меньшей нагрузки на стенку прямой кишки.</p></sec><sec><title>Заключение</title><p>Заключение. Выбор конкретного режима фракционирования должен определяться на основе рассчитанных значений дифференциальных гистограмм «доза–объем» для каждого пациента, а также из радиобиологических критериев, таких как TCP, NTCP и UTCP.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To determine the most effective irradiation regimen (total dose and dose per fraction) for hypofractionated treatment for prostate carcinomas according the TCP/NTCP radiobiological criteria.</p></sec><sec><title>Material and methods</title><p>Material and methods. Using the tomographic information of five patients with low-risk prostate adenocarcinoma as an example, the authors devised dosimetric radiation therapy plans using the volumetric modulated arc therapy (VMAT) procedure. They considered the range of total doses of 33.5 to 38 Gy administered in 4 and 5 fractions. Based on the equivalent uniform dose concept proposed by A. Niemierko and on the computed differential dose volume histograms, the investigators modeled local tumor control probability (TCP) values, by taking into account the uncertainties of main radiobiological parameters, and estimated normal tissue complication probabilities (NTCP) for the anterior rectal wall as the organ most at risk of irradiation. An effective dosimetric plan was selected according to the UTCP criterion and the probability of complication-free tumor control, i.e. TCP (1 – NTCP).</p></sec><sec><title>Results</title><p>Results. The results of modeling the UTCP criterion show that with a higher total dose, the TCP value increases and so does the NTCP value, therefore the optimal radiation therapy plans are to irradiate with a total dose of 34 Gy over 4 fractions or with a dose of 36–37 Gy over 5 fractions. The difference between the fractionation regimens is that the UTCP value is achieved with a higher TCP value over 4 fractions and with a lower load on the rectal wall over 5 fractions.</p></sec><sec><title>Conclusion</title><p>Conclusion. The choice of a specific fractionation regimen should be determined from the calculated values of differential dose volume histograms for each patient, as well as from radiobiological criteria, such as TCP, NTCP and UTCP.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>лучевая терапия</kwd><kwd>карцинома предстательной железы</kwd><kwd>гипофракционирование</kwd><kwd>вероятность локального контроля над опухолью</kwd><kwd>вероятность осложнений в нормальной ткани</kwd></kwd-group><kwd-group xml:lang="en"><kwd>radiation therapy</kwd><kwd>prostate carcinoma</kwd><kwd>hypofractionation</kwd><kwd>tumor control probability</kwd><kwd>normal tissue complications probability</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа была выполнена при частичной поддержке программы повышения конкурентоспособности Томского политехнического университета.</funding-statement><funding-statement xml:lang="en">The study was partly supported by Competitiveness Enhancement Program of Tomsk Polytechnic University.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lo S.S., Teh B.S., Lu J.J., Schefter T.E. (Eds.). Stereotactic body radiation therapy. Berlin Heidelberg: Springer-Verlag; 2012.</mixed-citation><mixed-citation xml:lang="en">Lo S.S., Teh B.S., Lu J.J., Schefter T.E. (Eds.). Stereotactic body radiation therapy. Berlin Heidelberg: Springer-Verlag; 2012.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Харченко В.П., Клеппер Л.Я., Панышин Г.А., Сотникова В.М., Даценко П.В. Математическое моделирование зависимости вероятности лимфомы Ходжкина от суммарной очаговой дозы. Медицинская физика. 2005; 4 (28): 28–35.</mixed-citation><mixed-citation xml:lang="en">Kharchenko V.P., Klepper L.Ya., Panyshin G.А., Sotnikova V.М., Datsenko P.V. Mathematical simulation of Hodgkin lymphoma probability dependence on total dose. Meditsinskaya Fizika (Medical Physics).2005; 4 (28): 28–35 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin. Radiat. Oncol. 2008; 18 (4): 234–9. DOI: 10.1016/j.semradonc.2008.04.004</mixed-citation><mixed-citation xml:lang="en">Brenner D.J. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin. Radiat. Oncol. 2008; 18 (4): 234–9. DOI: 10.1016/j.semradonc.2008.04.004</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Li X.A., Alber M., Deasy J.O., Jackson A., Jee K.W., Marks L.B. et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med. Phys. 2012; 39 (3): 1386–409. DOI: 10.1118/1.3685447</mixed-citation><mixed-citation xml:lang="en">Li X.A., Alber M., Deasy J.O., Jackson A., Jee K.W., Marks L.B. et al. The use and QA of biologically related models for treatment planning: short report of the TG-166 of the therapy physics committee of the AAPM. Med. Phys. 2012; 39 (3): 1386–409. DOI: 10.1118/1.3685447</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">National Radiotherapy Implementation Group Report. Stereotactic Body Radiotherapy Clinical Review of the Evidence for SBRT. NHS. National Cancer Action Team. Part of the National Cancer Programme. 2010: 13–25. Available at: http://www.academia.edu/978819/National_Radiotherapy_Implementation_Group_Report_Stereotactic_Body_Radiotherapy_Clinical_Review_of_the_Evidence_for_SBRT (accessed October 14, 2019).</mixed-citation><mixed-citation xml:lang="en">National Radiotherapy Implementation Group Report. Stereotactic Body Radiotherapy Clinical Review of the Evidence for SBRT. NHS. National Cancer Action Team. Part of the National Cancer Programme. 2010: 13–25. Available at: http://www.academia.edu/978819/National_Radiotherapy_Implementation_Group_Report_Stereotactic_Body_Radiotherapy_Clinical_Review_of_the_Evidence_for_SBRT (accessed October 14, 2019).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Benedict S.H., Yenice K.M., Followill D. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med. Phys. 2010; 37 (8): 4078–101. DOI: 10.1118/1.3438081</mixed-citation><mixed-citation xml:lang="en">Benedict S.H., Yenice K.M., Followill D. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med. Phys. 2010; 37 (8): 4078–101. DOI: 10.1118/1.3438081</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chatterjee S., Willis N., Locks S.M., Mott H., Kelly C.G. Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas. Br. J. Radiol. 2011; 84 (1008): 1083–90. DOI: 10.1259/bjr/53812025</mixed-citation><mixed-citation xml:lang="en">Chatterjee S., Willis N., Locks S.M., Mott H., Kelly C.G. Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas. Br. J. Radiol. 2011; 84 (1008): 1083–90. DOI: 10.1259/bjr/53812025</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med. Phys. 1997; 24 (1): 103–10. DOI: 10.1118/1.598063</mixed-citation><mixed-citation xml:lang="en">Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med. Phys. 1997; 24 (1): 103–10. DOI: 10.1118/1.598063</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Niemierko A.A. Unified model of tissue response to radiation. In: Proceedings of the 41th AAPM annual meeting. Nashville, Tennessee, 1999. Med. Phys. 1999: 1100.</mixed-citation><mixed-citation xml:lang="en">Niemierko A.A. Unified model of tissue response to radiation. In: Proceedings of the 41th AAPM annual meeting. Nashville, Tennessee, 1999. Med. Phys. 1999: 1100.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Diot Q., Kavanagh B., Timmerman R., Miften M. Biologicalbased optimization and volumetric modulated arc therapy delivery for stereotactic body radiation therapy. Med. Phys. 2012; 39 (1): 237–45. DOI: 10.1118/1.3668059</mixed-citation><mixed-citation xml:lang="en">Diot Q., Kavanagh B., Timmerman R., Miften M. Biologicalbased optimization and volumetric modulated arc therapy delivery for stereotactic body radiation therapy. Med. Phys. 2012; 39 (1): 237–45. DOI: 10.1118/1.3668059</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Geinitz H., Roach M. 3rd, van As N. (Eds.) Radiotherapy in prostate cancer innovative techniques and current controversies. Berlin Heidelberg: Springer-Verlag; 2015.</mixed-citation><mixed-citation xml:lang="en">Geinitz H., Roach M. 3rd, van As N. (Eds.) Radiotherapy in prostate cancer innovative techniques and current controversies. Berlin Heidelberg: Springer-Verlag; 2015.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kang S.W., Chung J.B., Kim J.S., Kim I.A., Eom K.Y., Song C. et al. Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique. Radiol. Oncol. 2017; 51 (1): 112–20. DOI: 10.1515/raon-2017-0005</mixed-citation><mixed-citation xml:lang="en">Kang S.W., Chung J.B., Kim J.S., Kim I.A., Eom K.Y., Song C. et al. Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique. Radiol. Oncol. 2017; 51 (1): 112–20. DOI: 10.1515/raon-2017-0005</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">RTOG/EORTC Late Radiation Morbidity Scoring Schema. Available at: https://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx (accessed October 14, 2019)</mixed-citation><mixed-citation xml:lang="en">RTOG/EORTC Late Radiation Morbidity Scoring Schema. Available at: https://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx (accessed October 14, 2019)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Semenenko V.A., Reitz B., Day E., Qi X.S., Miften M., Li X.A. Evaluation of a commercial biologically based IMRT treatment planning system. Med. Phys. 2008; 35 (12): 5851–60. DOI: 10.1118/1.3013556</mixed-citation><mixed-citation xml:lang="en">Semenenko V.A., Reitz B., Day E., Qi X.S., Miften M., Li X.A. Evaluation of a commercial biologically based IMRT treatment planning system. Med. Phys. 2008; 35 (12): 5851–60. DOI: 10.1118/1.3013556</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Ghandour S., Matzinger O., Pachouda M. Volumetric-modulated arc therapy planning using multicriteria optimization for localized prostate cancer. J. Appl. Clin. Med. Phys. 2015; 16 (3): 5410. DOI: 10.1120/jacmp.v16i3.5410</mixed-citation><mixed-citation xml:lang="en">Ghandour S., Matzinger O., Pachouda M. Volumetric-modulated arc therapy planning using multicriteria optimization for localized prostate cancer. J. Appl. Clin. Med. Phys. 2015; 16 (3): 5410. DOI: 10.1120/jacmp.v16i3.5410</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gregoire V., Mackie T.R., De Neve W., Gospodarowicz M., Purdy J.A., van Herk M., Niemierko A. Prescribing, recording, and reporting photon beam intensity-modulated radiation therapy (IMRT). ICRU Report No. 83. J. ICRU. 2010; 10 (1): 92. DOI: 10.1093/jicru/10.1.Report83</mixed-citation><mixed-citation xml:lang="en">Gregoire V., Mackie T.R., De Neve W., Gospodarowicz M., Purdy J.A., van Herk M., Niemierko A. Prescribing, recording, and reporting photon beam intensity-modulated radiation therapy (IMRT). ICRU Report No. 83. J. ICRU. 2010; 10 (1): 92. DOI: 10.1093/jicru/10.1.Report83</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Landberg T., Chavaudra J., Dobbs J., Gerard J.P., Hanks G., Horiot J.C. et al. Prescribing, recording, and reporting photon beam therapy. ICRU Report No. 62. J. ICRU. 1999; 32 (1): 52. DOI: 10.1093/jicru/os32.1.Report62</mixed-citation><mixed-citation xml:lang="en">Landberg T., Chavaudra J., Dobbs J., Gerard J.P., Hanks G., Horiot J.C. et al. Prescribing, recording, and reporting photon beam therapy. ICRU Report No. 62. J. ICRU. 1999; 32 (1): 52. DOI: 10.1093/jicru/os32.1.Report62</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dasu A., Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14168 patients. Acta Oncologica. 2012; 51 (8): 963–74. DOI: 10.3109/0284186X.2012.719635</mixed-citation><mixed-citation xml:lang="en">Dasu A., Toma-Dasu I. Prostate alpha/beta revisited – an analysis of clinical results from 14168 patients. Acta Oncologica. 2012; 51 (8): 963–74. DOI: 10.3109/0284186X.2012.719635</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 43 (5): 1095–101. DOI: 10.1016/s0360-3016(98)00438-6</mixed-citation><mixed-citation xml:lang="en">Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1999; 43 (5): 1095–101. DOI: 10.1016/s0360-3016(98)00438-6</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Levegrün S., Jackson A., Zelefsky M.J., Venkatraman E.S., Skwarchuk M.W., Schlegel W. et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother. Oncol. 2002; 63 (1): 11–26. DOI: 10.1016/s0167-8140(02)00062-2</mixed-citation><mixed-citation xml:lang="en">Levegrün S., Jackson A., Zelefsky M.J., Venkatraman E.S., Skwarchuk M.W., Schlegel W. et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother. Oncol. 2002; 63 (1): 11–26. DOI: 10.1016/s0167-8140(02)00062-2</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
